Home
Biocytogen Pharmaceuticals (Beijing) ...

Biocytogen Pharmaceutica... Market Share Analysis for March 2026

百奥赛图（股票代码：02315.HK），致力于成为全球新药发源地，以专注技术创新、持续新药产出、守护人类健康为使命。随着规模化抗体药物研发-“千鼠万抗”计划的实施，将更聚焦于创新抗体药物研发。

Health > Biotechnology and Pharmaceuticals

Domainbiocytogen.com.cn

Year Founded2009

Employees1001 - 5000

Annual Revenue--

Biocytogen Pharmaceuticals (Beijing) ...

Biocytogen Pharmaceuticals (Beijing) ... (including company regionals)

biocytogen.com.cn

See more website traffic and engagement information

Total visits to Biocytogen Pharmaceuticals (Beijing) ...'s top domains

Understand Biocytogen Pharmaceuticals (Beijing) ... market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biocytogen.com.cn2.5K

See more with Sales Intelligence

Avg. visit duration in Biocytogen Pharmaceuticals (Beijing) ...'s top domains

Analyze Biocytogen Pharmaceuticals (Beijing) ... engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biocytogen.com.cn00:00:16

See more with Sales Intelligence

Avg. pageviews on Biocytogen Pharmaceuticals (Beijing) ...'s top domains

See how Biocytogen Pharmaceuticals (Beijing) ... keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biocytogen.com.cn1.25

See more with Sales Intelligence

Biocytogen Pharmaceuticals (Beijing) ... top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Biocytogen Pharmaceuticals (Beijing) ...

These are the website technologies, by industry, used by Biocytogen Pharmaceuticals (Beijing) ... top domains

Advertising (6)

DoubleClick

Conversion & Analytics (3)

Google Analytics

Mobile (3)

Meta Viewport

Social (3)

Instagram

More Technologies

5

See all

News & Signals from Biocytogen Pharmaceuticals (Beijing) ...

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiocytogen JiangSu Co.,Ltd. partners with BeOne Medicines Ltd.Biocytogen enters into antibody licensing agreement with BeOne Medicines to accelerate innovative drug development.

NewsHarbour Biomed filed suit against Biocytogen JiangSu Co.,Ltd. on Sep 27th '24.On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent.

NewsBiocytogen JiangSu Co.,Ltd. integrates with Acepodia Inc..This collaboration combines Biocytogen's RenLite(R) platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology-tumor heterogeneity and drug resistance.